One Monday morning in September last year, Ron Fouchier, a virologist at the Erasmus Medical Center in Rotterdam, Netherlands, stood at the Intercontinental Hotel in Malta and told an audience of scientists about how he had created one of the world’s most dangerous viruses.
In a secure laboratory built to contain harmful pathogens, Fouchier took the H5N1 bird flu virus and mutated it, through some worryingly simple steps, into an airborne strain that spread swiftly among ferrets in neighboring cages. At first glance, the work might seem bad news for ferrets and little more, but the animals are the best mimic we have for how the virus could infect people, for example through coughs and sneezes.
The work went largely unnoticed until December, when the US government’s biosecurity watchdog, the National Science Advisory Board for Biosecurity (NSABB), raised the alarm. Though bird flu, as the name suggests, is mostly an avian disease, it has killed more than half the people known to have been infected. The only reason it has not become a global killer is that it does not spread easily from person to person. The NSABB declared a paper Fouchier had sent to it — and the US journal Science — too dangerous to publish. The board called for key sections of the report to be deleted, to prevent the recipe for the virus from falling into the hands of bioterrorists.
Fouchier was not alone in having his work black-marked. The NSABB urged similar restrictions on another paper sent to the British journal Nature. In that, Yoshihiro Kawaoka, a virology professor at the University of Wisconsin-Madison, merged bird flu with the highly transmissible swine flu virus to make a hybrid strain that also spread among ferrets through airborne droplets. The swine flu virus, which originated in pigs, went global in humans, but while it killed more than 18,000 in a 2009 pandemic, it was not as lethal as the WHO feared.
The advisory board’s reaction has sparked a rare crisis in science. The US government backed the NSABB, but many researchers say the work must be published in full, arguing public health will benefit. A group convened by the WHO recommended full disclosure, but ordered an urgent review of the security and safety of labs where such viruses are stored. In the meantime, work on mutant bird flu has halted under a voluntary moratorium.
The deadlock could soon be broken. On Thursday, the 23-strong NSABB gathered for a confidential two-day meeting in Washington to review updated versions of both papers, which in Fouchier’s case included fresh evidence that his virus is not as dangerous as some accounts first claimed. Fouchier and Kawaoka were to be brought in to answer queries directly. Whatever the panel’s final recommendations, they were likely to redefine how risky, dual-use research is handled in future.
There are solid scientific grounds for tinkering with the virus. Fouchier and Kawaoka’s experiments address a crucial question: Could bird flu evolve naturally into a form that spreads easily among people? Their work suggests it can. In Fouchier’s study it only took five mutations — all of which have been seen in the wild — for bird flu to become airborne and spread through ferrets. Kawaoka showed bird flu could achieve the same end by picking up other genes when it mixed with swine flu, an event that could happen naturally in pigs.
The search for a resolution to the impasse has been clouded by several factors that created a perfect storm over the issue. First are fears that a bird flu pandemic in humans might be extraordinarily lethal, perhaps more so than the Spanish 1918 flu virus which killed only 2 percent to 3 percent of those infected, but still claimed tens of millions of lives. Officially, 59 percent of the 600 or so people known to have caught bird flu have died. However, that figure is likely to be misleading, as mild cases may go unrecorded. Just how lethal a bird flu pandemic would be in humans is unknown. The second factor is the threat of bioterrorism. And third, comments in the press.
In November, Fouchier told Science that his strain of flu was “probably one of the most dangerous viruses you can make.”
NSABB head Paul Keim, who has worked extensively on anthrax, told the journal: “I can’t think of another pathogenic organism that is as scary as this one. I don’t think anthrax is scary at all compared to this.”
Secrecy over the research added to widespread confusion in the media over Fouchier’s virus in particular. While Kawaoka’s strain was not lethal to ferrets, several reports said Fouchier’s was. He later clarified that the airborne virus only killed ferrets when it was squeezed in large doses into their tracheas. Some animals that caught the virus by inhaling it from others got sick, but none of them died.
“Because of the confidentiality of reviewing the work, these details were not entirely clear and there were a lot of misconceptions out there. The lay public was really confused,” said Anthony Fauci, director of the US funding agency the National Institute of Allergy and Infectious Diseases (NIAID), who called Thursday’s NSABB meeting.
As a test case, the mutant flu papers have exposed what some consider serious shortcomings in the mechanisms that governments, funding agencies, scientists and journals have in place to handle potentially dangerous discoveries. The NSABB, for example, was oblivious to the work until October, when the journals were ready to publish the papers.
“It’s a lot of work to get an advisory board fully informed about specific research. To do it quickly and within the scientific publishing schedule is next to impossible,” Keim said. “The US government came close to killing us with the workload last fall. One committee member estimated that he devoted 200 hours to the problem in October and November.”
The NSABB’s call for redactions revealed other systemic problems. It wanted journals to publish the research with sensitive information removed. Only an approved list of scientists could then apply to read the sensitive information.
“It’s nonsense. Who chooses the 200 or 400 scientists around the world who get access? Who polices whether they immediately give it to their colleagues? It’s unworkable, unpoliceable and crazy to even consider. Once it’s out there, it’s out there,” said Jeremy Farrar, director of the Oxford University clinical research unit in Ho Chi Minh City, Vietnam.
When it comes to bird flu in humans, Farrar’s clinic is on the front line. Staff there treat patients who contract the virus and run surveillance for unusual strains in people and poultry, pigs and other animals. Last month, two men turned up in Ho Chi Minh City with bird flu infections that looked different from all the previous cases Farrar has witnessed in the past seven or eight years. The men, in their 20s, arrived from the countryside desperately sick. Tests confirmed they had H5N1 bird flu and X-rays of their lungs showed white, a clear sign of the damage the virus can cause. The outlook was bad for both, but within days, the men had recovered. The unusual cases raised questions for Farrar.
“What you are always looking for is a change in the way the disease presents itself and how the body responds. It makes you question whether the disease is adapting to humans. It’s pure speculation, but we could be seeing the process of adaptation going on in front of our eyes,” Farrar said.
The genetic mutations that made Fouchier and Kawaoka’s viruses so transmissible in ferrets would not necessarily be the same ones that help bird flu jump into humans. However, if the details were published, Farrar said he could at least screen for them and learn whether the mutations appear only singularly in the wild, or start appearing in clusters of twos, threes and fours. More importantly, knowing how the mutations transform the virus would help scientists spot other mutations that could make bird flu adapt to humans.
“All of this surveillance is not much value if the experimental work, which is mostly done in Western labs, is not made available to the countries where it’s most needed,” Farrar said.
One difficulty facing bird flu research is that surveillance picks up only a tiny fraction of the millions of viruses at large in the world. The chances of spotting a pandemic strain early enough to contain it are slim. For that reason, many scientists say the best we can do is prepare for the disease when it strikes.
“Forget all the nonsense about bioterrorism. These papers tell us that nature is where we should focus our concern,” said John Oxford, professor of virology the London School of Medicine and Dentistry. “The mutant strains that Fouchier and Kawaoka described are probably already out there. They must be out there. Fortunately for us, it is probably in some duck in Siberia, but were it to move close to hand by the vagaries and chances of nature, we’d be for it.”
Oxford and Farrar say that the mutant flu papers stress the need for governments to prepare for a dangerous, emergent flu strain. The British Department of Health has 16 million doses of the GlaxoSmithKline bird flu vaccine, Prepandrix, stockpiled with a shelf life of three to seven years. If bird flu jumped into humans, the frontline services, including doctors and nurses, would get priority for the jabs.
After the NSABB raised the alarm over Fouchier and Kawaoka’s papers, Fauci urged the WHO to take a look at the work. On Feb. 16, 22 people met in the WHO’s Geneva offices to thrash out a consensus. Fouchier, Kawaoka and Keim were there, with other flu researchers, journal editors and representatives from Indonesia and Vietnam, where bird flu is endemic. The group decided there was too little time to create a global mechanism to disseminate sensitive details from redacted papers to a chosen list of experts. Instead, they backed full publication, but only after a public awareness program to explain the importance of the research, and a review of the safety and security of mutant flu strains.
Many scientists at least agree with the WHO’s call for an urgent review of the safety and security surrounding mutant flu research. Laboratories where pathogens are handled are built to a biosafety level (BSL) ranked from one to four. Lethal agents such as the Ebola virus and smallpox are contained in the highest-level laboratories (BSL4). Both mutant flu studies were performed in BSL3 labs, which are considered more than adequate.
Even so, some countries have already upgraded their security around mutant bird flu work. In February, Canada ruled that all future research on strains of bird flu that are transmissible in mammals be confined to BSL4 laboratories.
“The institutes, the funding agencies, the scientists and the public need to be convinced there is absolute biosecurity so those viruses don’t leak out. That’s a major concern and it should have been dealt with at the time the work was funded,” Farrar said.
The NSABB’s final decision, which was due on Friday at the earliest, will be considered by the US government before being passed to Science and Nature, whose editors have expressed a preference to publish the papers in full. Whatever the fate of the mutant flu papers, moves toward a mechanism of distributing sensitive scientific information in future are likely to get a spur.
Fouchier fears the NSABB will pave the way to a precedent in censoring scientific publications and warns that an international agreement to allow selective distribution of sensitive information will be “laborious and time-consuming.”
The Dutch government has already insisted Fouchier applies for export licenses for his paper to be discussed at the WHO and Thursday’s NSABB meeting. It threatened to block publication of his paper unilaterally through the same legislation. Any country signing up to a secretive distribution system might have to rewrite its own laws on the export of information.
Efforts to draw up a distribution mechanism at the NIAID have made little headway.
“We’ve been trying to work it out, just in case the journals have to publish redacted versions, but we’re still trying to figure that out. The problem is, how do you give access to unredacted information?” Fauci said.
Fouchier has similar concerns.
“If the scientific community is expected to work via redacted papers and sharing of scientific information on a need-to-know basis in the future, then international governments better start to work toward systems to facilitate that. While this system is not in place, advice such as that from the NSABB last year simply cannot be followed,” he said.
Recently, China launched another diplomatic offensive against Taiwan, improperly linking its “one China principle” with UN General Assembly Resolution 2758 to constrain Taiwan’s diplomatic space. After Taiwan’s presidential election on Jan. 13, China persuaded Nauru to sever diplomatic ties with Taiwan. Nauru cited Resolution 2758 in its declaration of the diplomatic break. Subsequently, during the WHO Executive Board meeting that month, Beijing rallied countries including Venezuela, Zimbabwe, Belarus, Egypt, Nicaragua, Sri Lanka, Laos, Russia, Syria and Pakistan to reiterate the “one China principle” in their statements, and assert that “Resolution 2758 has settled the status of Taiwan” to hinder Taiwan’s
Singaporean Prime Minister Lee Hsien Loong’s (李顯龍) decision to step down after 19 years and hand power to his deputy, Lawrence Wong (黃循財), on May 15 was expected — though, perhaps, not so soon. Most political analysts had been eyeing an end-of-year handover, to ensure more time for Wong to study and shadow the role, ahead of general elections that must be called by November next year. Wong — who is currently both deputy prime minister and minister of finance — would need a combination of fresh ideas, wisdom and experience as he writes the nation’s next chapter. The world that
The past few months have seen tremendous strides in India’s journey to develop a vibrant semiconductor and electronics ecosystem. The nation’s established prowess in information technology (IT) has earned it much-needed revenue and prestige across the globe. Now, through the convergence of engineering talent, supportive government policies, an expanding market and technologically adaptive entrepreneurship, India is striving to become part of global electronics and semiconductor supply chains. Indian Prime Minister Narendra Modi’s Vision of “Make in India” and “Design in India” has been the guiding force behind the government’s incentive schemes that span skilling, design, fabrication, assembly, testing and packaging, and
As former president Ma Ying-jeou (馬英九) wrapped up his visit to the People’s Republic of China, he received his share of attention. Certainly, the trip must be seen within the full context of Ma’s life, that is, his eight-year presidency, the Sunflower movement and his failed Economic Cooperation Framework Agreement, as well as his eight years as Taipei mayor with its posturing, accusations of money laundering, and ups and downs. Through all that, basic questions stand out: “What drives Ma? What is his end game?” Having observed and commented on Ma for decades, it is all ironically reminiscent of former US president Harry